KeyNeurotek AG and Max Planck Society sign licence and cooperation agreement for drug development
KeyNeurotek AG has signed an exclusive licensing agreement with Max-Planck-Innovation GmbH. The license covers a method to identify drug candidates developed at the Max Planck Research Unit for Enzymology of Protein Folding (Halle/Saale). In addition to the licensing contract, the partners signed an amendment to an already existing exclusive collaboration agreement for drug development in the field of FK506 binding proteins. www.keyneurotek.de
Download PDF press release
News alert
Do you want to receive our newsletter and press releases?
Subscribe here
Media contact
Markus Berninger
Phone: (089) 290919-30